Results 31 to 40 of about 682 (125)

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study [PDF]

BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao, Daming Wang, Mengzhao Yang, Chunyu Zhao, Ming Cheng, Silin Li, Donghua Zhang, Hong Luo, Guowu Qian, Ling Wang, Shixi Zhang, Guotao Li, Guangming Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +2 more sources

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

View
Kidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective
Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan   +13 more
doaj   +2 more sources

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis. [PDF]

PLoS One
Objective The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Methods A search was carried out in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until October 20, 2023.
Amani B, Amani B.
europepmc   +3 more sources

Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study

Journal of Infection and Public Health
Background: Azvudine has become a widely used treatment for COVID-19 in China. Our study aimed to assess the real-world efficacy of azvudine in hospitalized COVID-19 patients during the omicron variant surge.
Daxiong Zeng, , Guanghe Fei
exaly   +3 more sources

A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years [PDF]

Acta Pharmaceutica Sinica B
Azvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known.
Bo Yu, Haiyu Wang, Guangming Li, Junyi Sun, Hong Luo, Mengzhao Yang, Yanyang Zhang, Ruihan Liu, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Quancheng Kan, Jiandong Jiang, Zhigang Ren   +17 more
doaj   +2 more sources

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundAzvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19.
Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng   +29 more
doaj   +3 more sources

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

View
Although azvudine has become a priority in the treatment of SARS‐CoV‐2, its effectiveness and safety among COVID‐19 patients who already have chronic respiratory diseases (CRDs) have not been sufficiently validated.
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
doaj   +2 more sources

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes [PDF]

iScience
Summary: Azvudine and nirmatrelvir-ritonavir are prioritized treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in hospitalized patients with COVID-19 and pre-existing diabetes remains unknown.
Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren   +18 more
doaj   +2 more sources

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

BMC Infectious Diseases
Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between ...
Peng Su, Cong-xian Yang, Xing-guang Wang
doaj   +3 more sources

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study

Scientific Reports
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19.
Mei-Ping Chen, Di-Xuan Jiang, Jia-Xi Rang, Hai-Bo Zhuo, Zhi-Guo Zhou   +4 more
exaly   +2 more sources